Cleo Diagnostics (ASX: COV) Takes Major Step Towards US FDA Approval With 1,470-Sample Ovarian Cancer Test Programme

Cleo Diagnostics (ASX: COV) has reached an important operational milestone after establishing its US clinical testing infrastructure, bringing its ovarian cancer blood test closer to the final major validation programme required for regulatory submission.

The 12 November 2026 announcement confirms that laboratory equipment has been installed and commissioned at Bio-Techne's US facility, with clinical testing expected to commence within the next month.

With approximately 1,470 samples planned for testing and an FDA submission targeted for the first half of 2027, Cleo is progressing towards a potentially significant commercial opportunity.

Key Numbers

• 1,470 samples: Planned across three US clinical validation studies.
• 19 clinical sites: Contributed to the pivotal US trial's sample collection.
• 92.2% sensitivity: Achieved in an earlier high-risk Stage I ovarian cancer screening study.
• $4.37 million: Cash reserves at 30 September 2026.
• First half of 2027: Targeted FDA 510(k) submission for Cleo's pre-surgical diagnostic test.

US laboratory milestone brings clinical validation closer

Cleo's latest announcement confirms that three Bio-Techne Ella automated immunoassay instruments have been installed and commissioned at Asuragen, its CLIA-certified US clinical laboratory partner.

This establishes the infrastructure required to undertake clinical validation of Cleo's Pre-Surgical Ovarian Cancer Test.

Importantly, inter-laboratory reproducibility studies are now underway between Cleo's Melbourne facility and Asuragen.

These studies will assess whether the diagnostic assay produces consistent results across both laboratories using the same manufacturing batch.

Demonstrating reproducibility is essential because regulatory authorities require evidence that diagnostic performance remains reliable across different testing environments.

For Cleo, this represents meaningful progress towards transforming its diagnostic technology into a commercially deployable product.

A 1,470-sample programme could strengthen the FDA submission

Cleo's clinical validation programme will evaluate approximately 1,470 samples across three distinct study populations.

The pivotal clinical performance study will assess approximately 600 prospectively collected samples from its US trial, conducted across 19 sites.

This study will examine the test's ability to distinguish benign from malignant ovarian disease in women presenting with suspicious ovarian masses.

A further 570 samples will assess potential interference from other benign and malignant conditions, while approximately 300 samples from healthy women will establish expected test-score distributions.

Together, these studies are designed to generate clinical sensitivity and specificity data within the product's intended application.

The resulting evidence, combined with ongoing analytical validation, will support Cleo's planned FDA 510(k) submission.

Clinical testing is anticipated to commence within the next month, following receipt of test kits at Asuragen.

However, successful validation and regulatory clearance remain necessary before commercialisation can proceed.

Earlier screening results highlight broader market potential

Cleo's immediate commercial priority is its pre-surgical test, but its longer-term screening programme provides another potential growth opportunity.

On 21 October 2026, the company reported 92.2% sensitivity and 98.7% specificity for Stage I ovarian cancer detection in a retrospective high-risk screening study.

The results suggest potential for earlier diagnosis, although larger independent studies are needed to confirm clinical performance.

Cleo has also filed two provisional patent applications covering screening-related biomarker combinations.

This staged development strategy could eventually create opportunities across pre-surgical testing, recurrence monitoring and broader ovarian cancer screening.

However, these markets remain at different development stages and should not be treated as established revenue sources.

Cash reserves remain important as regulatory work accelerates

Cleo's September quarter reflected the increasing expenditure associated with its clinical and regulatory programmes.

Net operating cash outflows reached approximately $3.33 million, including $2.76 million in research and development payments.

Cash reserves stood at $4.37 million at 30 September 2026, representing approximately 1.3 quarters of funding at the September expenditure rate.

Management anticipates expenditure fluctuations and expects a research and development tax incentive refund during the December quarter.

While these factors could support near-term liquidity, future funding requirements remain important.

Without established commercial revenue, Cleo's valuation depends largely on successful validation, regulatory clearance, future adoption and achievable margins.

Insight: Clinical readiness strengthens Cleo's commercial opportunity

What stands out to us is Cleo's progress from diagnostic development towards operational readiness for US regulatory validation. Establishing laboratory infrastructure and preparing a 1,470-sample programme provide tangible evidence of execution, while earlier screening results demonstrate broader technological potential. We see an encouraging opportunity if Cleo delivers reproducible clinical performance and secures sufficient funding to support commercialisation. The next decisive milestones are the commencement of clinical testing, validation results and progress towards its planned FDA submission.

The verdict: Cleo is entering a defining development phase

Cleo's latest announcement strengthens its commercialisation outlook by confirming that critical US laboratory infrastructure is operational.

Its diagnostic technology has demonstrated encouraging potential, while the planned clinical programme provides a clearer pathway towards regulatory assessment.

The key priorities now are completing analytical and clinical validation, finalising the commercial assay algorithm and maintaining sufficient funding.

Successful execution could position Cleo for an important transition towards commercial adoption, making its upcoming clinical results and FDA submission progress particularly significant.